The analytic framework section depicts a flow diagram outlines the population, interventions and outcomes considered in the DMARDs review. This figure depicts the key questions within the context of the PICOTS described in the previous section. In general, the figure illustrates how treatment of JIA in children with DMARDs versus intra-articular corticosteroids and NSAIDs may result in intermediate outcomes (e.g., changes in laboratory measures of inflammation, changes in the active joint count, or radiologically evident progression of disease) and/or long-term outcomes (e.g., clinical remission, changes in quality of life, changes in growth, and changes in development). In addition, adverse events may occur at any point after the treatment is received.

Appendix Figure B2Example analytic framework

* Measures used in the “ACR Pediartic 30” definition of improvement

Note: CRP=C-reactive protein, DMARD= disease-modifying anti-rheumatic drug, ESR = erythrocyte sedimentation rate, KQ = key question, ROM=.range of motion

From: Appendix B, Example of Selected Aspects of a Topic Refinement

Cover of The Refinement of Topics for Systematic Reviews
The Refinement of Topics for Systematic Reviews: Lessons and Recommendations From the Effective Health Care Program [Internet].
Buckley DI, Ansari M, Butler M, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.